Search results

Found 40 releases mentioning: pradaxa

Business Wire Australia and New Zealand

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

21 Mar 2018

Business Wire Australia and New Zealand

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

16 Nov 2017

Business Wire Australia and New Zealand

New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in Pradaxa® (dabigatran etexilate) patients with gastrointestinal bleeding or needing emergency surgery

15 Nov 2017

Business Wire Australia and New Zealand

CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics

18 Sep 2017

Business Wire Australia and New Zealand

Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement

28 Aug 2017

Business Wire Australia and New Zealand

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 2017

21 Aug 2017

Business Wire Australia and New Zealand

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

11 Jul 2017

Business Wire Australia and New Zealand

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients

21 Jun 2017

Business Wire Australia and New Zealand

Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation

21 Mar 2017

Business Wire Australia and New Zealand

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients

06 Dec 2016

Business Wire Australia and New Zealand

Patient enrolment completed for RE-DUAL PCI™ study assessing dabigatran in atrial fibrillation patients after PCI with stenting

12 Nov 2016

Business Wire Australia and New Zealand

Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice

16 Aug 2016

Display

Sort by

Your saved searches

If you regularly search for a topic or keyword, you can save the current search criteria for quick access in future. Saved searches will be listed here.

Refine results